top of page

What's your post-op regimen?

effectively maintains pupil dilation

and requires less use of PEDs¹⁻⁶

Reduces complications

such as IFIS, CME, and breakthrough iritis⁷⁻⁸

improveS patient experience

with less pain, greater visual acuity, and no to fewer drops¹˒³˒⁷

Stay ahead of the unexpected

OMIDRIA, the only FDA-approved intracameral NSAID

OMIDRIA blocks the inflammatory cascade before it starts and leads to positive patient outcomes

Learn more about OMIDRIA

Preferred contact from local Rayner representative:

OMIDRIA is the 1st and only FDA-approved non-opioid, NSAID-containing treatment for maintaining pupil size and reducing postoperative pain by preventing intraoperative miosis.¹

  • 96% of OMIDRIA-treated patients had pupil diameter ≥6 mm at the start of lens implantation¹˒¹³˒²⁰

  • Real-world evidence shows that OMIDRIA can benefit ALL patient types, not just high-risk patients²˒⁴⁻⁸˒¹⁷˒¹⁹

OMIDRIA effectively maintains pupil dilation

Indications and Usage

OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

Important Safety Information

OMIDRIA must be added to irrigating solution prior to intraocular use.

OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.
Systemic exposure to phenylephrine may cause elevations in blood pressure.
Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.
The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.
Please see the Full Prescribing Information for OMIDRIA.
You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Optimize time.
Maximize control.

surgeon.png

Learn more about OMIDRIA

Thank you for submitting your details, a member of the Rayner team will be in touch soon.

Please visit our main website to discover more about OMIDRIA:

Don't miss what your peers are saying at Peer2Peer:

  1. OMIDRIA [package insert]. Bellevue, WA: Rayner Surgical Inc. April 2023.

  2. Rosenberg ED, Nattis AS, Alevi D, et al. Visual outcomes, efficacy, and surgical complications associated with intracameral phenylephrine 1.0%/ketorolac 0.3% administered during cataract surgery. Clin Ophthalmol. 2018;12:21-28.

  3. Al-Hashimi S, Donaldson K, Davidson R, et al. Medical and surgical management of the small pupil during cataract surgery. J Cataract Refract Surg. 2018;44(8):1032-1041.

  4. Bucci FA Jr, Michalek B, Fluet AT. Comparison of the frequency of use of a pupil expansion device with and without an intracameral phenylephrine and ketorolac injection 1%/0.3% at the time of routine cataract surgery. Clin Ophthalmol. 2017;11:1039-1043.

  5. Walter K, Delwadia N, Coben J. Continuous intracameral phenylephrine–ketorolac irrigation for miosis prevention in femtosecond laser–assisted cataract surgery: reduction in surgical time and iris manipulation. J Cataract Refract Surg. 2019;45(4):465-469.

  6. Visco D. Effect of phenylephrine/ketorolac on iris fixation ring use and surgical times in patients at risk of intraoperative miosis. Clin Ophthalmol. 2018;12:301-305.

  7. Silverstein SM, Rana VK, Stephens R, et al. Effect of phenylephrine 1.0%–ketorolac 0.3% injection on tamsulosin-associated intraoperative floppy-iris syndrome. J Cataract Refract Surg. 2018;44(9):1103-1108.

  8. Visco DM, Bedi R. Effect of intracameral phenylephrine 1.0%–ketorolac 0.3% on postoperative cystoid macular edema, iritis, pain, and photophobia after cataract surgery. J Cataract Refract Surg. 2020;46(6):867-872.

  9. An JA, Kasner O, Samek DA, Lévesque V. Evaluation of eyedrop administration by inexperienced patients after cataract surgery. J Cataract Refract Surg. 2014;40(11):1857-1861.

  10. Wielders LHP, Schouten JSAG, Winkens B, et al, for the ESCRS PREMED Study Group. European multicenter trial of the prevention of cystoid macular edema after cataract surgery in nondiabetics: ESCRS PREMED study report 1. J Cataract Refract Surg. 2018;44:429-439.

  11. Donnenfeld ED, Hovanesian JA, Malik AG, Wong A. A randomized, prospective, observer-masked study comparing dropless treatment regimen using intracanalicular dexamethasone insert, intracameral ketorolac, and intracameral moxifloxacin versus conventional topical therapy to control postoperative pain and inflammation in cataract surgery. Clin Ophthalmol. 2023;17:2349-2356.

  12. Lindstrom RL, Galloway MS, Grzybowski A, Liegner JT. Dropless cataract surgery: an overview. Curr Pharm Des. 2017;23(4):558–564.

  13. Rayner. Data on file.

  14. Donnenfeld EDD. Blocking the inflammatory cascade. CRST. Accessed August 30, 2024. https://crstoday.com/articles/blocking-the-inflammatory-cascade/blocking-the-inflammatory-cascade

  15. Waterbury LD. Alternative drug delivery for patients undergoing cataract surgery as demonstrated in a canine model. J Ocular Pharmacol Ther. 2018;34(1-2):154-160.

  16. Wittpenn JR, Silverstein S, Heier J, Kenyon KR, Hunkeler JD, Earl M; Acular LS for Cystoid Macular Edema (ACME) Study Group. A randomized, masked comparison of topical ketorolac 0.4%plus steroid vs steroid alone in low-risk cataract surgery patients. Am J Ophthalmol. 2008;146:554–560.

  17. Donnenfeld ED, Shojaei RD. Effect of intracameral phenylephrine and ketorolac 1.0%/0.3% on intraoperative pain and opioid use during cataract surgery. Clin Ophthalmol. 2019;13:2143-2150.

  18. Hovanesian JA, Sheppard JD, Trattler WB, et al. Intracameral phenylephrine and ketorolac during cataract surgery to maintain intraoperative mydriasis and reduce postoperative ocular pain: integrated results from 2 pivotal phase 3 studies. J Cataract Refract Surg. 2015;41:2060-2068.

  19. Donnenfeld ED, Whitaker JS, Jackson MA, Wittpenn J. Intracameral ketorolac and phenylephrine effect on intraoperative pupil diameter and postoperative pain in cataract surgery. J Cataract Refract Surg. 2017;43(5):597-605.

  20. Lindstrom RL, Loden JC, Walters TR, et al. Intracameral phenylephrine and ketorolac injection (OMS302) for maintenance of intraoperative pupil diameter and reduction of postoperative pain in intraocular lens replacement with phacoemulsification. Clin Ophthalmol. 2014;8:1735-1744.

  21. Matossian C. Clinical and economic outcomes in cataract surgery using phenylephrine 1.0%-ketorolac 0.3% in a real-world setting. Presented at: ASCRS ASOA Annual Meeting 2018; April 13-17, 2018; Washington, DC.

Rayner, the Rayner logo, OMIDRIA, the OMIDRIA logo, and OMIDRIAssure are proprietary marks of Rayner.

© 2025 Rayner Group, all rights reserved. US-OM-2400063 10/24

Reduces complication rates²

OMIDRIA reduces the use of PEDs and surgical time

  • Mean surgical time with OMIDRIA was significantly shorter compared to epinephrine (10.1 vs 14.3 minutes; P=0.0068) in high-risk patients⁷

  • Mean surgical time with OMIDRIA was significantly shorter compared to epinephrine (8.10 vs 9.39 minutes; P=0.007) in femtosecond laser-assisted cataract surgeries⁵

Indications and Usage

OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

Important Safety Information

OMIDRIA must be added to irrigating solution prior to intraocular use.

OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.
Systemic exposure to phenylephrine may cause elevations in blood pressure.
Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.
The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.
Please see the Full Prescribing Information for OMIDRIA.
You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

bottom of page